

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

INSIDE INFORMATION ANNOUNCEMENT

STRATEGIC COLLABORATION WITH SANDOZ

A. INTRODUCTION

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors of the Company is pleased to announce that on 16 August 2026, the Company entered into a framework collaboration agreement (the “**Framework Collaboration Agreement**”) with Sandoz AG (“**Sandoz**”), together with the product annexes for the first batch of collaboration products and terms on an option for a potential collaboration product (the “**Collaboration**”). According to the agreements referred to above, the invoiced amount in an aggregate of no more than USD100.5 million is expected to be achieved in 2026, subject to the satisfaction of the terms and conditions agreed by the parties.

B. PRINCIPAL TERMS OF THE FRAMEWORK COLLABORATION AGREEMENT

Strategic Collaboration The Framework Collaboration Agreement will cover up to 10 monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components, as may be agreed upon by both parties from time to time (the “**Collaboration Product(s)**”). The parties shall enter into product annexes from time to time to agree on the specific details of the collaboration for each product. Pursuant to which, the Company and Sandoz establish a global strategic partnership, and the scope of the Collaboration covers CMC development, pre-clinical development, clinical development, regulatory submissions, manufacturing, launch, commercialization and life cycle management of the Collaboration Products.

The Company will be responsible for the development, manufacture and supply of the Collaboration Products, and grant Sandoz an exclusive license to register and commercialize the Collaboration Products in the territory and a co-exclusive license to develop and manufacture the Collaboration Products in the territory, unless provided otherwise in product annexes. Sandoz shall pay the Company the upfront payments, relevant milestone payments and/or sales shares as well as other payments for each Collaboration Product which shall be agreed specifically in each product annex. Sandoz will be responsible for obtaining and maintaining marketing authorizations (MA) for the Collaboration Products in the territory as well as the commercialization of the Collaboration Products in the territory.

Territory	Worldwide excluding Chinese Mainland and Hong Kong, Macau and Taiwan regions of China, unless otherwise specified in product annexes.
Field	For all indications in humans, solely to the extent corresponding to the indications for which the reference product has received regulatory approval in the relevant jurisdiction.
Term	The Framework Collaboration Agreement shall come into effect as of the date of execution and remain in effect perpetually, unless earlier terminated in accordance with the terms therein.

C. PRINCIPAL TERMS FOR THE FIRST BATCH OF COLLABORATION PRODUCTS

First Batch of Collaboration Products	3 of the Collaboration Products which have been agreed by parties, being Cetuximab biosimilar HLX05-N, Evolocumab biosimilar HLX16 and Belimumab biosimilar.
Territory for the First Batch of Collaboration Products	In respect of HLX05-N, the exclusive territories to register and commercialize shall cover the United States, Canada, the countries of the European Economic Area, Switzerland, the United Kingdom, Japan, Australia, and New Zealand; and the semi-exclusive territories to register and commercialize shall cover agreed certain countries/regions in Asia as well as other regions. In respect of HLX16 and Belimumab biosimilar, the exclusive territories to register and commercialize shall cover worldwide excluding Chinese Mainland and Hong Kong, Macau and Taiwan regions of China.

Payments

In respect of the collaboration of the first batch of collaboration products, Sandoz shall pay the Company:

- (a) Upfront payments of the relevant product in an aggregate amount of up to USD77 million, payable within the agreed period following the execution of the Framework Collaboration Agreement;
- (b) Development milestone payments and budgeted development milestone payments of the relevant product in an aggregate amount of up to USD160 million, payable based on the achievements of respective milestone events for relevant products or within the agreed period;
- (c) Commercial milestone payments of the relevant product in an aggregate amount of up to USD77 million, payable based on the achievements of respective commercial milestone events for the relevant products; and
- (d) 40% of the net sales or net profits of the relevant product in each country within respective territory, unless otherwise agreed.

D. OPTION FOR THE POTENTIAL COLLABORATION ON HLXTE-HAASE1001

Within the agreed period following the execution of the Framework Collaboration Agreement, Sandoz will pay the Company a non-refundable option payment of USD8 million regarding the potential collaboration on the hyaluronidase HLXTE-HAase1001. Upon exercising the option, the parties will reach specific cooperation arrangements, and Sandoz will pay the Company agreed amounts of development milestone payments, sales milestone payments as well as tiered commercial rewards as agreed.

E. INFORMATION ABOUT THE COLLABORATION PRODUCTS

The first batch of collaboration products comprises Cetuximab biosimilar HLX05-N, Evolocumab biosimilar HLX16 and Belimumab biosimilar, the potential Collaboration Product with option is Hyaluronidase HLXTE-HAase1001.

HLX05-N is a cetuximab injection biosimilar independently developed by the Company, intended for the treatment of metastatic colorectal cancer and head and neck squamous cell carcinoma. In July 2026, the first patient has been dosed in a phase 1 clinical study of cetuximab injection biosimilar HLX05-N independently developed by the Company in patients with metastatic colorectal cancer (mCRC) in Chinese Mainland (excluding Hong Kong, Macau and Taiwan regions). Currently, this product is in phase 1 clinical study trial stage. According to the statistics released by IQVIA MIDAS™ (IQVIA is a global provider of professional information and strategic consulting services in the pharmaceutical and healthcare industry), the sales revenues of cetuximab injection globally amounted to approximately USD1.696 billion in 2025.

HLX16 is an evolocumab biosimilar independently developed by the Company, intended for the treatment of primary hypercholesterolaemia (including heterozygous familial and non-familial types). Currently, this product is in the preclinical research stage. According to the statistics released by IQVIA MIDAS™ (IQVIA is a global provider of professional information and strategic consulting services in the pharmaceutical and healthcare industry), the sales revenues of evolocumab injection globally amounted to approximately USD6.602 billion in 2025.

Belimumab biosimilar, independently developed by the Company, is intended for the treatment of systemic lupus erythematosus and lupus nephritis. Currently, this product is in the preclinical research stage. According to the statistics released by IQVIA MIDAS™ (IQVIA is a global provider of professional information and strategic consulting services in the pharmaceutical and healthcare industry), the sales revenues of belimumab injection globally amounted to approximately USD2.475 billion in 2025.

HLXTE-HAase1001 is a recombinant human hyaluronidase independently developed by the Company, intended to transform time-consuming intravenous infusion into rapid subcutaneous injection, thereby significantly shortening administration time and improving patient experience. Currently, this product is in the process development stage. As of the date of this announcement, approximately 10 combination therapy protocols containing recombinant human hyaluronidase have been approved for marketing globally, covering fields such as tumors, autoimmunity, immunodeficiency, and neurological diseases.

The parties may also agree from time to time to include additional Collaboration Products in accordance with the agreement.

F. REASONS AND BENEFITS OF THE COLLABORATION

The Company has previously established a good cooperative relationship with Sandoz for the commercialisation of ipilimumab biosimilar HLX13 across various regions globally. The Collaboration may leverage the Company's strengths in development and manufacturing, and Sandoz's global market leading position and infrastructure for commercialization of biosimilars to bring high quality biosimilars to patients across the globe, which deepens overseas expansion process of the Company's products, further enhances the accessibility and influence of the Company's products in the international markets, and is expected to provide more treatment options for patients in the territory.

G. INFORMATION ABOUT SANDOZ

Sandoz AG was incorporated in 1979, with its heritage dating back to 1886, and is headquartered in Basel, Switzerland. Sandoz is a wholly-owned subsidiary of Sandoz Group AG, which is listed on the SIX Swiss Exchange (stock code: SDZ). Sandoz Group AG is specialized in the development, manufacturing and marketing of biosimilar and generic medicines, with its presence covering more than 100 countries.

WARNING STATEMENT WITH REFERENCE TO THE REQUIREMENTS UNDER RULE 18A.05 OF THE RULES GOVERNING THE LISTING OF SECURITIES ON THE STOCK EXCHANGE OF HONG KONG LIMITED: The Company cannot guarantee the successful development and commercialization of the Collaboration Products. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 17 August 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.